Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 6/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | F13A1 | P00488 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | TGM1 | P22735 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5916557 | 1.00 | CYP3A4 (0.50) | CYP3A4MMP13KDM4EL3MBTL1CXCR3 | |
| SCHEMBL5916529 | 1.00 | CYP3A4 (0.50) | CYP3A4MMP13KDM4EL3MBTL1CXCR3 | |
| SCHEMBL14259938 | 0.90 | CYP3A4 (0.59) | CYP3A4MMP13KDM4EL3MBTL1CXCR3 | |
| SCHEMBL5916508 | 0.85 | CYP3A4 (0.40) | CYP3A4MMP13KDM4EMMP7 | |
| SCHEMBL5916509 | 0.85 | CYP3A4 (0.40) | CYP3A4MMP13KDM4EMMP7 | |
| SCHEMBL6645919 | 0.81 | MMP7 (0.40) | CYP3A4MMP13KDM4ESMN1; SMN2GAA | |
| SCHEMBL5916458 | 0.81 | MMP7 (0.42) | CYP3A4MMP13KDM4EL3MBTL1GAA | |
| SCHEMBL5916453 | 0.81 | MMP7 (0.42) | CYP3A4MMP13KDM4EL3MBTL1GAA | |
| SCHEMBL5916456 | 0.81 | MMP7 (0.42) | CYP3A4MMP13KDM4EL3MBTL1GAA | |
| SCHEMBL6647638 | 0.80 | MMP7 (0.38) | CYP3A4MMP13KDM4EL3MBTL1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153857-B2 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-20060229313-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | US | disclosed |
| US-20040220185-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | US | disclosed |
| EP-1417201-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | AstraZeneca AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003014111-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229313-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | CYP3A4 264/4885MMP13 1/4885KDM4E 2014/4885 |
| US-20040220185-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | CYP3A4 277/4885MMP13 1/4885KDM4E 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.